Pembrolizumab can also be given as monotherapy for the first-line treatment of NSCLC patients with PD-L1 expression on ≥ 50% of tumor cells as the phase III KEYNOTE-024 study showed that it improved PFS and OS and had a better toxicity profile compared to platinum-based chemotherapy [115]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.